Balyasny Asset Management’s Acceleron Pharma XLRN Stock Holding History

Balyasny Asset Management’s Portfolio XLRN Stock Details XLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-140,492	Closed	-$24.2M	–	2768
2021 Q3	$24.2M	Buy	+140,492	New	+$18.4M	0.1%	277
2018 Q4	–	Sell	-7,476	Closed	-$428K	–	1897
2018 Q3	$428K	Sell	7,476 -715	-9%	-$35.1K	﹤0.01%	1421
2018 Q2	$397K	Buy	+8,191	New	+$298K	﹤0.01%	1423
2018 Q1	–	Sell	-58,500	Closed	-$2.48M	–	2449
2017 Q4	$2.48M	Buy	+58,500	New	+$2.19M	0.01%	1078

Balyasny Asset Management's XLRN Position: Q4 2021 in Review

Balyasny Asset Management sold out of Acceleron Pharma (XLRN) in Q4 2021, closing a stake of 140,492 shares — an estimated $24.2M sold.

Balyasny Asset Management first reported a position in XLRN in Q4 2017 and held it in 4 quarters. The position peaked at $24.2M in Q3 2021. 1 fund tracked by Wall St. Rank holds XLRN as of Q4 2021.

Balyasny Asset Management reported no remaining Acceleron Pharma position as of Q4 2021 after selling out during the quarter.
Balyasny Asset Management sold 140,492 Acceleron Pharma shares in Q4 2021, an estimated $24.2M.
Balyasny Asset Management first reported a position in Acceleron Pharma in Q4 2017 and held it in 4 quarters.
Balyasny Asset Management's Acceleron Pharma position peaked at $24.2M in Q3 2021.
1 fund tracked by Wall St. Rank held Acceleron Pharma as of Q4 2021.

Based on Balyasny Asset Management's 13F filing for Q4 2021, filed 14 Feb 2022.